The expression profile of phosphatidylinositol in high spatial resolution imaging mass spectrometry as a potential biomarker for prostate cancer

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Goto, Takayuki ^a   Terada, Naoki ^a   Inoue, Takahiro ^a   Nakayama, Kenji ^a   Okada, Yoshiyuki ^a   Yoshikawa, Takeshi ^a   Miyazaki, Yu ^a   Uegaki, Masayuki ^a   Sumiyoshi, Shinji ^b   Kobayashi, Takashi ^a   Kamba, Tomomi ^a   Yoshimura, Koji ^a   Ogawa, Osamu ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PHOSPHATIDIC ACID; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLINOSITOL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CANCER TISSUE; CLINICAL ARTICLE; DIAGNOSTIC TEST ACCURACY STUDY; HIGH RESOLUTION MATRIX ASSISTED LASER IONIZATION IMAGING MASS SPECTROMETRY; HUMAN; HUMAN TISSUE; LIPID ANALYSIS; MALE; MASS SPECTROMETRY; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

AGED; ALGORITHMS; HUMANS; MALE; MIDDLE AGED; PHOSPHATIDIC ACIDS; PHOSPHATIDYLETHANOLAMINES; PHOSPHATIDYLINOSITOLS; PROSTATECTOMY; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84896504556     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090242     Document Type: Article

References (46)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30.
2. Santos CR, Schulze A (2012) Lipid metabolism in cancer. FEBS J 279: 2610-2623.
3. Menendez JA, Lupu R (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7: 763-777. (Pubitemid 47469806)
4. Schulze A, Harris AL (2012) How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 491: 364-373.
5. Rysman E, Brusselmans K, Scheys K, Timmermans L, Derua R, et al. (2010) De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res 70: 8117-8126.
6. van Meer G, de Kroon AI (2011) Lipid map of the mammalian cell. J Cell Sci 124: 5-8.
7. Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296: 1655-1657. (Pubitemid 34579158)
8. Li J, Yen C, Liaw D, Podsypanina K, Bose S, et al. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947. (Pubitemid 27148818)
9. Sarker D, Reid AH, Yap TA, de Bono JS (2009) Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 15: 4799-4805.
10. Holub BJ, Kuksis A, Thompson W (1970) Molecular species of mono-, di-, and triphosphoinositides of bovine brain. J Lipid Res 11: 558-564.
11. Gijon MA, Riekhof WR, Zarini S, Murphy RC, Voelker DR (2008) Lysophospholipid acyltransferases and arachidonate recycling in human neutrophils. J Biol Chem 283: 30235-30245.
12. Kawashima M, Iwamoto N, Kawaguchi-Sakita N, Sugimoto M, Ueno T, et al. (2013) High-resolution imaging mass spectrometry reveals detailed spatial distribution of phosphatidylinositols in human breast cancer. Cancer Sci 104: 1372-1379.
13. Caprioli RM, Farmer TB, Gile J (1997) Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. Anal Chem 69: 4751-4760.
14. Kubo A, Ohmura M, Wakui M, Harada T, Kajihara S, et al. (2011) Semiquantitative analyses of metabolic systems of human colon cancer metastatic xenografts in livers of superimmunodeficient NOG mice. Anal Bioanal Chem 400: 1895-1904.
15. Schober Y, Guenther S, Spengler B, Rompp A (2012) Single cell matrix-assisted laser desorption/ionization mass spectrometry imaging. Anal Chem 84: 6293-6297.
16. Miura D, Fujimura Y, Yamato M, Hyodo F, Utsumi H, et al. (2010) Ultrahighly sensitive in situ metabolomic imaging for visualizing spatiotemporal metabolic behaviors. Anal Chem 82: 9789-9796.
17. Yasunaga M, Furuta M, Ogata K, Koga Y, Yamamoto Y, et al. (2013) The significance of microscopic mass spectrometry with high resolution in the visualisation of drug distribution. Sci Rep 3: 3050.
18. Kurabe N, Hayasaka T, Ogawa M, Masaki N, Ide Y, et al. (2013) Accumulated phosphatidylcholine (16:0/16:1) in human colorectal cancer; possible involvement of LPCAT4. Cancer Sci 104: 1295-1302.
19. Schwartz SA, Reyzer ML, Caprioli RM (2003) Direct tissue analysis using matrix-assisted laser desorption/ionization mass spectrometry: practical aspects of sample preparation. J Mass Spectrom 38: 699-708. (Pubitemid 36950300)
20. Chaurand P, Norris JL, Cornett DS, Mobley JA, Caprioli RM (2006) New developments in profiling and imaging of proteins from tissue sections by MALDI mass spectrometry. J Proteome Res 5: 2889-2900. (Pubitemid 44749207)
21. Terada N, Shimizu Y, Kamba T, Inoue T, Maeno A, et al. (2010) Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model. Cancer Res 70: 1606-1615.
22. Crowe FL, Allen NE, Appleby PN, Overvad K, Aardestrup IV, et al. (2008) Fatty acid composition of plasma phospholipids and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 88: 1353-1363.
23. Freeman VL, Flanigan RC, Meydani M (2007) Prostatic fatty acids and cancer recurrence after radical prostatectomy for early-stage prostate cancer. Cancer Causes Control 18: 211-218. (Pubitemid 46215317)
24. Zhou X, Mao J, Ai J, Deng Y, Roth MR, et al. (2012) Identification of plasma lipid biomarkers for prostate cancer by lipidomics and bioinformatics. PLoS One 7: e48889.
25. Xie Y, Gibbs TC, Mukhin YV, Meier KE (2002) Role for 18:1 lysophosphatidic acid as an autocrine mediator in prostate cancer cells. J Biol Chem 277: 32516-32526. (Pubitemid 34984755)
26. Zeng Y, Kakehi Y, Nouh MA, Tsunemori H, Sugimoto M, et al. (2009) Gene expression profiles of lysophosphatidic acid-related molecules in the prostate: relevance to prostate cancer and benign hyperplasia. Prostate 69: 283-292.
27. Pchejetski D, Golzio M, Bonhoure E, Calvet C, Doumerc N, et al. (2005) Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res 65: 11667-11675. (Pubitemid 41821727)
28. Simons K, Ikonen E (1997) Functional rafts in cell membranes. Nature 387: 569-572. (Pubitemid 27248754)
29. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR (2005) Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 115: 959-968. (Pubitemid 40489400)
30. Schwamborn K, Caprioli RM (2010) Molecular imaging by mass spectrometry-looking beyond classical histology. Nat Rev Cancer 10: 639-646.
31. Enomoto H, Sugiura Y, Setou M, Zaima N (2011) Visualization of phosphatidylcholine, lysophosphatidylcholine and sphingomyelin in mouse tongue body by matrix-assisted laser desorption/ionization imaging mass spectrometry. Anal Bioanal Chem 400: 1913-1921.
32. Ishikawa S, Tateya I, Hayasaka T, Masaki N, Takizawa Y, et al. (2012) Increased expression of phosphatidylcholine (16:0/18:1) and (16:0/18:2) in thyroid papillary cancer. PLoS One 7: e48873.
33. Eberlin LS, Dill AL, Costa AB, Ifa DR, Cheng L, et al. (2010) Cholesterol sulfate imaging in human prostate cancer tissue by desorption electrospray ionization mass spectrometry. Anal Chem 82: 3430-3434.
34. Cazares LH, Troyer D, Mendrinos S, Lance RA, Nyalwidhe JO, et al. (2009) Imaging mass spectrometry of a specific fragment of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 2 discriminates cancer from uninvolved prostate tissue. Clin Cancer Res 15: 5541-5551.
35. Schwamborn K, Krieg RC, Reska M, Jakse G, Knuechel R, et al. (2007) Identifying prostate carcinoma by MALDI-Imaging. Int J Mol Med 20: 155-159.
36. Bonnel D, Longuespee R, Franck J, Roudbaraki M, Gosset P, et al. (2011) Multivariate analyses for biomarkers hunting and validation through on-tissue bottom-up or in-source decay in MALDI-MSI: application to prostate cancer. Anal Bioanal Chem 401: 149-165.
37. Pallua JD, Schaefer G, Seifarth C, Becker M, Meding S, et al. (2013) MALDIMS tissue imaging identification of biliverdin reductase B overexpression in prostate cancer. J Proteomics 91C: 500-514.
38. Pirro V, Eberlin LS, Oliveri P, Cooks RG (2012) Interactive hyperspectral approach for exploring and interpreting DESI-MS images of cancerous and normal tissue sections. Analyst 137: 2374-2380.
39. Steurer S, Borkowski C, Odinga S, Buchholz M, Koop C, et al. (2013) MALDI mass spectrometric imaging based identification of clinically relevant signals in prostate cancer using large-scale tissue microarrays. Int J Cancer 133: 920-928.
40. Rawicz W, Olbrich KC, McIntosh T, Needham D, Evans E (2000) Effect of chain length and unsaturation on elasticity of lipid bilayers. Biophys J 79: 328-339. (Pubitemid 30436749)
41. Ben Gedalya T, Loeb V, Israeli E, Altschuler Y, Selkoe DJ, et al. (2009) Alphasynuclein and polyunsaturated fatty acids promote clathrin-mediated endocytosis and synaptic vesicle recycling. Traffic 10: 218-234.
42. Lee HC, Kubo T, Kono N, Kage-Nakadai E, Gengyo-Ando K, et al. (2012) Depletion of mboa-7, an enzyme that incorporates polyunsaturated fatty acids into phosphatidylinositol (PI), impairs PI 3-phosphate signaling in Caenorhabditis elegans. Genes Cells 17: 748-757.
43. Schmid AC, Wise HM, Mitchell CA, Nussbaum R, Woscholski R (2004) Type II phosphoinositide 5-phosphatases have unique sensitivities towards fatty acid composition and head group phosphorylation. FEBS Lett 576: 9-13. (Pubitemid 39330448)
44. Trygg J, Holmes E, Lundstedt T (2007) Chemometrics in metabonomics. J Proteome Res 6: 469-479. (Pubitemid 46340151)
45. Wiklund S, Johansson E, Sjostrom L, Mellerowicz EJ, Edlund U, et al. (2008) Visualization of GC/TOF-MS-based metabolomics data for identification of biochemically interesting compounds using OPLS class models. Anal Chem 80: 115-122. (Pubitemid 351448411)
46. Chan EC, Pasikanti KK, Nicholson JK (2011) Global urinary metabolic profiling procedures using gas chromatography-mass spectrometry. Nat Protoc 6: 1483-1499.